DefendentiCAtzeniFSpinaMF. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev2011; 10: 150–154.
4.
ReedJHClancyRMLeeKHSaxenaAIzmirlyPMBuyonJP. Umbilical cord blood levels of maternal antibodies reactive with p200 and full length Ro52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care Res (Hoboken)2012; 64: 1373–1381.
5.
ReedJHClancyRMPurcellAWKimMYGordonTPBuyonJP. beta2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. J Immunol2011; 187: 520–526.
6.
BehinAMayerMKassis-MakhoulB. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord2008; 18: 443–446.
7.
LewisKAEngleWHainlineBEJohnsonNCorkinsMEugsterEA. Neonatal Graves’ disease associated with severe metabolic abnormalities. Pediatrics2011; 128: e232–e236.
8.
FainOMathieuELachassinneE. Neonatal Behcet's disease. Am J Med1995; 98: 310–311.
AmbrosioPLermannRCordeiroABorgesANogueiraISerranoF. Lupus and pregnancy – 15 years of experience in a tertiary center. Clin Rev Allergy Immunol2010; 38: 77–81.
11.
IzmirlyPMSaxenaAKimMY. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation2011; 124: 1927–1935.
12.
BrucatoAFrassiMFranceschiniF. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum2001; 44: 1832–1835.
13.
BrucatoADoriaAFrassiM. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus2002; 11: 716–721.
14.
BuyonJPHiebertRCopelJ. Autoimmune-associated congenital heart block: Demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol1998; 31: 1658–1666.
15.
IzmirlyPMLlanosCLeeLAAskanaseAKimMYBuyonJP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum2010; 62: 1153–1157.
16.
LlanosCIzmirlyPMKatholiM. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum2009; 60: 3091–3097.
17.
LeeLA. Transient autoimmunity related to maternal autoantibodies: Neonatal lupus. Autoimmun Rev2005; 4: 207–213.
18.
NeimanARLeeLAWestonWLBuyonJP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr2000; 137: 674–680.
WatsonRKangJEMayMHudakMKicklerTProvostTT. Thrombocytopenia in the neonatal lupus syndrome. Arch Dermatol1988; 124: 560–563.
22.
CimazRSpenceDLHornbergerLSilvermanED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr2003; 142: 678–683.
CarpenterRJJrStrasburgerJFGarsonAJrSmithRTDeterRLEngelhardtHTJr. Fetal ventricular pacing for hydrops secondary to complete atrioventricular block. J Am Coll Cardiol1986; 8: 1434–1436.
25.
LindopRArentzGThurgoodLAReedJHJacksonMWGordonTP. Pathogenicity and proteomic signatures of autoantibodies to Ro and La. Immunol Cell Biol2012; 90: 304–309.
26.
MirandaMETsengCERashbaumW. Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J Immunol1998; 161: 5061–5069.
27.
KarnabiEQuYWadgaonkarR. Congenital heart block: Identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun2010; 34: 80–86.
28.
Wahren-HerleniusMSonessonSE. Specificity and effector mechanisms of autoantibodies in congenital heart block. Curr Opin Immunol2006; 18: 690–696.
29.
SirenMKJulkunenHKaajaREkbladHKoskimiesS. Role of HLA in congenital heart block: susceptibility alleles in children. Lupus1999; 8: 60–67.
30.
SaxenaAMcDonnellERamosPS. Preferential transmission of genetic risk variants of candidate loci at 6p21 from asymptomatic grandparents to mothers of children with neonatal lupus. Arthritis Rheum2012; 64: 931–939.
31.
SetiadyYYCocciaJAParkPU. In vivo depletion of CD4+FOXP3+Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+phagocytes. Eur J Immunol2010; 40: 780–786.
32.
StevensAMHermesHMRutledgeJCBuyonJPNelsonJL. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet2003; 362: 1617–1623.
33.
SaleebSCopelJFriedmanDBuyonJP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: Retrospective review of the research registry for neonatal lupus. Arthritis Rheum1999; 42: 2335–2345.
34.
IzmirlyPMCostedoat-ChalumeauNPisoniCN. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation2012; 126: 76–82.
35.
Zurgil NBRTincaniAFadenD. Detection of antiphospholipid and anti-DNA antibodies and their idiotypes in newborns of mothers with antiphospholipid syndrome and SLE. Lupus1993; 2: 233–237.
36.
O'CarrollPBertoriniTEJacobGMitchellCWGraffJ. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis. J Clin Neuromuscul Dis2009; 11: 69–71.
37.
ThapaRPramanikSDharSKunduR. Neonatal Kawasaki disease with multiple coronary aneurysms and thrombocytopenia. Pediatr Dermatol2007; 24: 662–663.
38.
BhattMAnilSRSivakumarKKumarK. Neonatal Kawasaki disease. Indian J Pediatr2004; 71: 353–354.
39.
BolzDArbenzUFanconiSBauersfeldU. Myocarditis and coronary dilatation in the 1st week of life: neonatal incomplete Kawasaki disease?Eur J Pediatr1998; 157: 589–591.
40.
TsuchidaSYamanakaTTsuchidaRNakamuraYYashiroMYanagawaH. Epidemiology of infant Kawasaki disease with a report of the youngest neonatal case ever reported in Japan. Acta Paediatr1996; 85: 995–997.
